Johnson & Johnson

For the patients, customers, and employees who depend on Johnson & Johnson, Supply Chain Resilience strengthens the company’s ability to consistently deliver, providing confidence and assurance through times of uncertainty.

Johnson & Johnson launched its Supply Chain Resilience programmes across its Pharmaceutical and MedTech sectors.

Supply Chain Resilience creates end-to-end visibility to vulnerabilities through quantifying Value at Risk, which is the measurement of the current variance if the node is disrupted and translated into net trade sales.

This end-to-end supply chain visibility focuses on mitigations that strengthen the company’s impact on healthcare, deliver confident and quantifiable decisions that drive growth, and build trust with its patients and customers.

In 2022, the Supply Chain Resilience programme launched a Resilience Dashboard which provides both high-level and in-depth information across products and nodes within different product value streams across the J&J enterprise.

The Resilience programme has uncovered unknown supply chain nodes and identified opportunities to strengthen supplier relationships and strategically adjust safety stock at the most vulnerable nodes.